- Home
- PERI vs MREO Comparison
PERI vs MREO Comparison
Compare PERI & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERI
- MREO
- Stock Information
- Founded
- PERI 1999
- MREO 2015
- Country
- PERI Israel
- MREO United Kingdom
- Employees
- PERI N/A
- MREO N/A
- Industry
- PERI EDP Services
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- PERI Technology
- MREO Health Care
- Exchange
- PERI Nasdaq
- MREO Nasdaq
- Market Cap
- PERI 484.6M
- MREO 438.8M
- IPO Year
- PERI 2006
- MREO N/A
- Fundamental
- Price
- PERI $10.22
- MREO $2.71
- Analyst Decision
- PERI Buy
- MREO Strong Buy
- Analyst Count
- PERI 4
- MREO 5
- Target Price
- PERI $11.50
- MREO $7.60
- AVG Volume (30 Days)
- PERI 225.3K
- MREO 1.4M
- Earning Date
- PERI 07-30-2025
- MREO 08-12-2025
- Dividend Yield
- PERI N/A
- MREO N/A
- EPS Growth
- PERI N/A
- MREO N/A
- EPS
- PERI N/A
- MREO N/A
- Revenue
- PERI $429,808,000.00
- MREO N/A
- Revenue This Year
- PERI N/A
- MREO N/A
- Revenue Next Year
- PERI $11.24
- MREO $52.34
- P/E Ratio
- PERI N/A
- MREO N/A
- Revenue Growth
- PERI N/A
- MREO N/A
- 52 Week Low
- PERI $7.00
- MREO $1.58
- 52 Week High
- PERI $11.79
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- PERI 56.20
- MREO 51.60
- Support Level
- PERI $9.28
- MREO $2.63
- Resistance Level
- PERI $10.04
- MREO $2.85
- Average True Range (ATR)
- PERI 0.30
- MREO 0.14
- MACD
- PERI 0.01
- MREO -0.02
- Stochastic Oscillator
- PERI 79.20
- MREO 16.27
About PERI Perion Network Ltd.
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).